UsAgainstAlzheimer’s Launches 2024 Brain Health Academy
16 avr. 2024 10h48 HE
|
UsAgainstAlzheimer's
WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s today announced the return of its Brain Health Academy, scheduled to begin on May 9, 2024. First launched in 2022, the Academy...
Congress Passes Bills Making Major Investments in Alzheimer’s
23 mars 2024 10h15 HE
|
UsAgainstAlzheimer's
Congress passes major investments in the fight against Alzheimer’s.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
11 mars 2024 08h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s
08 mars 2024 07h55 HE
|
UsAgainstAlzheimer's
WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the...
Global Neurological Biomarkers Market Analysis Report 2024-2030 - CAGR of 12.8% - Increased Funding For R&D in Biomarkers to Boost Development of New Drugs
24 janv. 2024 05h40 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism),...
For people living with dementia, support changes everything. The Alzheimer Society connects Albertans to dementia-friendly support, knowledge, and community.
02 janv. 2024 13h17 HE
|
Alzheimer Society of Alberta and NWT
Edmonton, Jan. 02, 2024 (GLOBE NEWSWIRE) -- A diagnosis of dementia is not easy. During National Alzheimer’s Awareness Month in January, the ALZHEIMER SOCIETY OF ALBERTA AND NORTHWEST TERRITORIES...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
04 déc. 2023 07h09 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
14 nov. 2023 05h28 HE
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults
30 oct. 2023 08h30 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development
Allyx Therapeutics to Present Phase 1 Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer's Disease Meeting
19 oct. 2023 16h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.